Testosterone Cypionate
FDA-approved product (injectable, injection), marketed as Azmiro, Depo-Testosterone, Testosterone Cypionate.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Hypogonadism
- Hypogonadotropic hypogonadism
- Klinefelter's syndrome
- Neoplasm
- Orchitis
- Physiological sexual disorder
- Sexual dysfunction
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- 3-oxoandrosten (4) derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli32.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Testosterone Cypionate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
NCT01378299 · start 2011-10-01
Registered record
- Registry ID
- NCT01378299
- Conditions
- Hypogonadism
- Interventions
- Testosterone Cypionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-10-01
- Completion
- 2017-11-07
- Enrolment
- 105
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypogonadismInterventionTestosterone CypionatePhasePhase 1Registry statusCompletedA Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
NCT01084759 · start 2010-03
Registered record
- Registry ID
- NCT01084759
- Conditions
- Prostate Cancer
- Interventions
- Testosterone injection; Etoposide
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2010-03
- Completion
- 2014-10
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionTestosterone injection; EtoposidePhaseNot applicableRegistry statusCompletedTestosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
NCT00965341 · start 2009-09
Registered record
- Registry ID
- NCT00965341
- Conditions
- Advanced Cancer
- Interventions
- Testosterone; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-09
- Completion
- 2012-09
- Enrolment
- 53
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAdvanced CancerInterventionTestosterone; PlaceboPhasePhase 3Registry statusCompletedThe Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa
NCT00853502 · start 2008-12
Registered record
- Registry ID
- NCT00853502
- Conditions
- Bone Metabolism
- Interventions
- testosterone cypionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2008-12
- Completion
- 2016-10
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBone MetabolismInterventiontestosterone cypionatePhasePhase 2Registry statusWithdrawnTreatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo
NCT00179517 · start 2001-06
Registered record
- Registry ID
- NCT00179517
- Conditions
- Seizure Disorder; Hypogonadism; Erectile Dysfunction
- Interventions
- Anastrozole 1mg; Placebo Oral Tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2008-04
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeizure Disorder; Hypogonadism; Erectile DysfunctionInterventionAnastrozole 1mg; Placebo Oral TabletPhasePhase 2Registry statusCompleted